Alt
/content/dam/asset-migration/headshots/uk-doctor-headshots/UK_Consultant_Headshot_GA_Mr-Alastair-D-Lamb.jpeg

Mr Alastair Lamb

Mr Alastair Lamb
Alastair
Lamb
MA(Oxon), MBChB, PhD(Cantab), FRCS(Urol) Consultant Urological Surgeon

Languages spoken

English

Expert in

Prostate Cancer

Overview

Centres

Oxford
Oxford

Peters Way, Sandy Lane West, Oxford, OX4 6LB

51.7239071200697, -1.2145938932540707
/uk/our-centres/oxford
+44 (0)1865 237 700
mediahawkNumber3680 mhMobile

Specialises in

Prostate cancer
Condition
Condition/Cancer
Condition/Cancer/Prostate cancer

Treatments

177Lutetium PSMA therapy
Service
Service/Cancer
Service/Cancer/Theranostics
Service/Cancer/Theranostics/177Lutetium PSMA therapy

Born in Edinburgh, but growing up and schooled in South Oxfordshire, Mr Lamb did initial medical training at Oxford (Corpus Christi College) and Edinburgh Universities, followed by registrar training as an ACF/ACL in Cambridge from 2007 – 2016. During this time,  he did his PhD with Professor David Neal on the molecular genetics of prostate cancer at the CRUK Cambridge Institute. Mr Lamb undertook specialty fellowship training with Associate Professor Declan Murphy at Peter MacCallum Cancer Centre in Melbourne, Australia 2016-2017 before appointment by Professor Freddie Hamdy to an academic consultant post in Oxford in April 2017.

Career positions

Current position(s)

  • Consultant Urologist

Expertise and interests

Expertise

  • Prostate cancer

Interest

  • Mr Lamb’s clinical focus is to deliver excellent and timely prostate cancer care to men referred to the team from the Oxford regional area, focussing on state-of-the-art diagnostics with multiparametric MRI and targeted transperineal biopsies, followed by robotic-radical prostatectomy (RARP) or indeed active surveillance where appropriate. Complimentary treatment modalities such as radiation or brachytherapy are provided by other members of the dedicated prostate cancer team. Mr Lamb has a particular interest in pushing the boundaries of minimal access surgery (MIS), for example to performing cytoreductive radical prostectomy in locally advanced or metastatic disease and RARP in fit, older men where such approaches are deemed safe and evidence-based.
  • Mr Lamb’s research goal is to provide a robust molecular platform for accurate decision-making in early stage prostate cancer. He has spent his scientific training investigating how individual genes or groups of genes have driven prostate cancer behaviour.
  • Mr Lamb’s PhD thesis investigated the role of HES6 as a transcriptional driver in castrate resistant prostate cancer – it was found that this single gene fundamentally changed the nature of prostate cancer cells. During this time, Mr Lamb was funded by the Cambridge Biomedical Research Centre (NIHR) and GlaxoSmithKline, and also by a Raymond and Beverly Sackler Studentship. Since then, he has been employing integrative genomics in prostate cancer risk stratification as well as disease modelling with patient derived xenografts.
  • Mr Lamb also has an interest in novel molecular imaging techniques such as 68Ga-PSMA PET/CT and their use in disease stratification and selection of patients for surgery. He is a local investigator for the ProMOTE, PART and TRoMbone studies.